<DOC>
	<DOCNO>NCT00651261</DOCNO>
	<brief_summary>The purpose study compare effect , good and/or bad , standard chemotherapy regimen AML include drug daunorubicin cytarabine combine without midostaurin ( also know PKC412 ) , find well . This research do unknown whether addition midostaurin chemotherapy treatment well chemotherapy treatment alone . Midostaurin test 400 patient studied number illness , include AML , colon cancer , lung cancer . Midostaurin block enzyme , produce gene know FLT3 , may role survival growth AML cell . Not leukemia cell abnormal FLT3 gene . This study focus patient leukemia cell abnormal FLT3 gene .</brief_summary>
	<brief_title>Daunorubicin , Cytarabine , Midostaurin Treating Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>In study , patient receive either experimental agent ( midostaurin ) placebo combine chemotherapy treatment . Patients stratify accord FLT3 mutation status ( internal tandem duplication [ ITD ] allelic ratio &lt; 0.7 v ITD allelic ratio ≥ 0.7 v tandem kinase domain [ TKD ] ) . There three part study treatment : remission induction therapy , remission consolidation therapy continuation therapy . Remission Induction Therapy : - Cytarabine 200 mg/m2/day continuous intravenous infusion day 1-7 - Daunorubicin 60 mg/m2/day intravenous push short infusion day 1-3 - Midostaurin 50 mg ( two 25 mg capsule ) placebo midostaurin ( 2 capsule ) twice day mouth day 8-21 - A bone marrow aspiration perform patient Day 21 determine need second induction cycle . Remission Consolidation ( Four Remission Consolidation Cycles ) : - High dose cytarabine 3000 mg/m2 give intravenous infusion 3 hour every 12 hour day 1 , 3 5 . Serial neurologic evaluation perform follow infusion high-dose cytarabine . - Dexamethasone 0.1 % corticosteroid ophthalmic solution 2 drop eye daily begin 6-12 hour prior initiation cytarabine infusion continue least 24 hour last cytarabine dose . - Midostaurin 50 mg ( two 25 mg capsule ) placebo midostaurin ( 2 capsule ) twice day mouth day 8-21 Midostaurin/Placebo Continuation Therapy : - Midostaurin 50 mg ( two 25 mg capsule ) placebo midostaurin ( 2 capsule ) mouth twice day 28 day . Each cycle 28 day length . Continuation therapy midostaurin/placebo continue relapse 12 cycle maximum . The primary secondary objective study : Primary objective : - To determine addition midostaurin daunorubicin/cytarabine induction , high-dose cytarabine consolidation , continuation therapy improve overall survival ( OS ) mutant FLT3-ITD FLT3-TKD AML patient Secondary objective : - To compare overall survival ( OS ) two group use analysis patient receive stem cell transplant censor time transplant - To compare complete response ( CR ) rate two treatment group - To compare event-free survival ( EFS ) two treatment group - To compare disease free survival ( DFS ) two treatment group - To compare disease free survival rate one year completion continuation phase two group - To assess toxicity experimental combination - To describe interaction treatment outcome pretreatment characteristic age , performance status , white blood cell ( WBC ) count , morphology , cytogenetics , molecular pharmacodynamic feature - To assess population pharmacokinetics ( popPK ) midostaurin two major metabolite ( CGP52421 CGP62221 ) . The potential association ( ) PK exposure FLT3 status , OS , EFS clinical response explore There pharmacokinetic sub-study ( CALGB 60706 ) within CALGB 10603 . This embedded companion study must offer patient enrol CALGB 10603 , although patient may opt participate CALGB 60706 . After study entry , patient follow periodically 10 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>4'-N-benzoylstaurosporine</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>1 . Documentation Disease : Unequivocal diagnosis AML ( &gt; 20 % blast bone marrow base WHO classification ) , exclude M3 ( acute promyelocytic leukemia ) . Patients neurologic symptom suggestive CNS leukemia recommend lumbar puncture . Patients whose CSF positive AML blast eligible . Documented FLT3 mutation ( ITD point mutation ) , determine analysis protocol designate FLT3 screen laboratory . 2 . Age Requirement : Age ≥ 18 &lt; 60 year 3 . Prior Therapy : No prior chemotherapy leukemia myelodysplasia follow exception : emergency leukapheresis emergency treatment hyperleukocytosis hydroxyurea ≤ 5 day cranial RT CNS leukostasis ( one dose ) growth factor/cytokine support AML patient history antecedent myelodysplasia ( MDS ) remain eligible treatment trial , must prior cytotoxic therapy ( e.g. , azacitidine decitabine ) Patients develop therapy relate AML prior RT chemotherapy another cancer disorder eligible . 4 . Cardiac Function : Patients symptomatic congestive heart failure eligible . 5 . Initial Laboratory Value : Total bilirubin &lt; 2.5 x ULN ( Upper Limit Normal ) 6 . Pregnancy Nursing Status : Nonpregnant nonnursing due unknown teratogenic potential midostaurin human , pregnant nursing patient may enrol . Women childbearing potential must negative serum urine pregnancy test within sensitivity least 50 mIU/mL within 16 day prior registration . Women childbearing potential must either commit continued abstinence heterosexual intercourse commit TWO acceptable method birth control : one highly effective method ( eg , IUD , hormonal ( nonoral contraceptive ) , tubal ligation , partner 's vasectomy ) one additional effective method ( e.g. , latex condom , diaphragm cervical cap ) The two acceptable method birth control must use AT THE SAME TIME , begin midostaurin/placebo therapy continue 12 week completion therapy . Note oral contraceptive consider high effective method possibility drug interaction midostaurin . Women childbearing potential define sexually active mature woman undergone hysterectomy menses time precede 24 consecutive month . Men must agree father child must use latex condom sexual contact woman childbearing potential take midostaurin/placebo 12 week therapy stop , even undergone successful vasectomy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
</DOC>